Liver Transplantation for Small Hepatocellular Carcinoma

Overview

Journal Hepatobiliary Surg Nutr

Publisher AME Publishing Company

Date 2016 Nov 10

PMID 27826553

Citations 7

Authors

Naoko Kamo

Toshimi Kaido

Shintaro Yagi

Hideaki Okajima

Shinji Uemoto

Affiliations

Soon will be listed here.

Abstract

Background: We treat small hepatocellular carcinoma (HCC) ≤3 cm in diameter by liver transplantation (LT) considering liver reserve and HCC localization, and when other treatment would be ineffective. However, the outcomes of LT and the clinicopathological features of small HCC ≤3 cm in diameter are not clear. We analyzed the outcomes of LT for small HCC ≤3 cm in diameter.

Methods: Between February 1999 and August 2015, 223 patients underwent LT for HCC at Kyoto University Hospital. We analyzed the proportion of small HCC ≤3 cm in diameter (small HCC) among all patients, the background of small HCC, survival and recurrence rates within and beyond the Milan criteria (MC), Kyoto criteria (KC) [≤5 cm, N ≤10, des-gamma-carboxy prothrombin (DCP) ≤400], and rates of survival and recurrence after LT with or without pretreatment.

Results: Among the 223 patients, 159 (71%) had small HCC accompanied by hepatitis B virus (HBV), 43 (27%); hepatitis C virus (HCV), 96 (61%); HBV, HCV, 5 (3%) and non B non C, 15 (9%). One hundred and fourteen (72%) patients were male with a tumor radius of 2 (range, 0.4-3) cm; number of tumors, 2 (range, 1-186); alpha-fetoprotein (AFP) 28.5 (range, 1.3-12,727) and DCP 42 (range, 5-20,600). The tumors were well, moderately and poorly differentiated in 22 (14%), 105 (66%) and 24 (15%) patients, respectively. Among the patients, 124 (78%) and 132 (83%) were within the MC and KC, respectively. One-, three- and five-year survival rates associated with tumors within and beyond the MC were 87%, 81% and 79% 94%, 76%, and 70%, respectively (P=0.430) and recurrence rates were significantly lower in patients within MC than in patients beyond MC (P<0.001). One-, three- and five-year survival rates associated with tumors within and beyond KC were 89%, 85%, and 83% 89%, 58%, and 50%, respectively (P<0.001) and recurrence rates were 2%, 3%, and 4% 21%, 37%, and 47%, respectively (P<0.001). Survival and recurrence rates were significantly higher and lower, respectively, among patients whose tumors were within, than beyond the KC. The one, three and five-year survival rates of patients with or without pretreatment were 89%, 79%, and 75% 86%, 81%, and 81%, respectively (P=0.315) and recurrence rates were 6%, 10%, and 15% 2%, 2%, and 2%, respectively (P=0.040). Recurrence rates were significantly higher in patients with pretreatment than in those without pretreatment.

Conclusions: Outcomes after LT were favorable for patients with small HCC that meet MC criteria or are less biologically malignant.

Citing Articles

Advancing microvascular invasion diagnosis: a multi-center investigation of novel MRI-based models for precise detection and classification in early-stage small hepatocellular carcinoma (≤ 3 cm).

Gu M, Zhang S, Zou W, Zhao X, Chen H, He R Abdom Radiol (NY). 2024; .

PMID: 39333413 DOI: 10.1007/s00261-024-04463-w.

Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms.

Guo J, Yan W, Duan H, Wang D, Zhou Y, Feng D Nutrients. 2024; 16(11).

PMID: 38892575 PMC: 11174683. DOI: 10.3390/nu16111642.

Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma.

Li Z, Jiao D, Han X, Si G, Li Y, Liu J Cancer Imaging. 2020; 20(1):13.

PMID: 32000862 PMC: 6993318. DOI: 10.1186/s40644-020-0294-5.

F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches.

Kornberg A, Friess H Therap Adv Gastroenterol. 2019; 12:1756284819836205.

PMID: 30915167 PMC: 6429646. DOI: 10.1177/1756284819836205.

Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas.

Wei Y, Dai F, Yi Y, Ye W, Zhao W Oncol Lett. 2018; 16(4):5050-5058.

PMID: 30250572 PMC: 6144377. DOI: 10.3892/ol.2018.9263.

References

Toso C, Asthana S, Bigam D, Shapiro A, Kneteman N . Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009; 49(3):832-8. DOI: 10.1002/hep.22693. View

Takada Y, Ito T, Ueda M, Sakamoto S, Haga H, Maetani Y . Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Dig Dis. 2007; 25(4):299-302. DOI: 10.1159/000106908. View

Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H . High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer. 2009; 115(3):571-80. DOI: 10.1002/cncr.24031. View

Ninomiya M, Harada N, Shiotani S, Hiroshige S, Minagawa R, Soejima Y . Hepatocyte growth factor and transforming growth factor beta1 contribute to regeneration of small-for-size liver graft immediately after transplantation. Transpl Int. 2003; 16(11):814-9. DOI: 10.1007/s00147-003-0628-9. View

Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K . Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013; 154(5):1053-60. DOI: 10.1016/j.surg.2013.04.056. View

Morioka D, Egawa H, Kasahara M, Ito T, Haga H, Takada Y . Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience with 335 consecutive cases. Ann Surg. 2007; 245(2):315-25. PMC: 1876999. DOI: 10.1097/01.sla.0000236600.24667.a4. View

Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M . Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol. 2007; 42(12):962-8. DOI: 10.1007/s00535-007-2117-x. View

Kokudo N, Makuuchi M . Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol. 2009; 44 Suppl 19:119-21. DOI: 10.1007/s00535-008-2244-z. View

. Global battle against cancer won't be won with treatment alone--effective prevention measures urgently needed to prevent cancer crisis. Cent Eur J Public Health. 2014; 22(1):23, 28. View

10.

Starzl T, Iwatsuki S, Van Thiel D, Gartner J, Zitelli B, Malatack J . Evolution of liver transplantation. Hepatology. 1982; 2(5):614-36. PMC: 2972731. DOI: 10.1002/hep.1840020516. View

11.

Inomata Y, Uemoto S, Asonuma K, Egawa H . Right lobe graft in living donor liver transplantation. Transplantation. 2000; 69(2):258-64. DOI: 10.1097/00007890-200001270-00011. View

12.

Fisher R, Kulik L, Freise C, Lok A, Shearon T, Brown Jr R . Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007; 7(6):1601-8. PMC: 3176596. DOI: 10.1111/j.1600-6143.2007.01802.x. View

13.

Sugawara Y, Tamura S, Makuuchi M . Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25(4):310-2. DOI: 10.1159/000106910. View

14.

Ito T, Kiuchi T, Egawa H, Kaihara S, Oike F, Ogura Y . Surgery-related morbidity in living donors of right-lobe liver graft: lessons from the first 200 cases. Transplantation. 2003; 76(1):158-63. DOI: 10.1097/01.TP.0000072372.42396.47. View

15.

Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y . Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009; 16(10):2795-804. DOI: 10.1245/s10434-009-0618-y. View

16.

Kurokawa T, Yamazaki S, Mitsuka Y, Moriguchi M, Sugitani M, Takayama T . Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin. Br J Cancer. 2015; 114(1):53-8. PMC: 4716541. DOI: 10.1038/bjc.2015.423. View

17.

Gomaa A, Khan S, Leen E, Waked I, Taylor-Robinson S . Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009; 15(11):1301-14. PMC: 2658831. DOI: 10.3748/wjg.15.1301. View

18.

Mazzaferro V, Llovet J, Miceli R, Bhoori S, Schiavo M, Mariani L . Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2008; 10(1):35-43. DOI: 10.1016/S1470-2045(08)70284-5. View

19.

Lo C, Fan S, Liu C, Chan S, Ng I, Wong J . Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg. 2006; 94(1):78-86. DOI: 10.1002/bjs.5528. View

20.

Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y . Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl. 2006; 12(6):912-9. DOI: 10.1002/lt.20642. View